{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin&page=2", "query": { "intervention": "Dapagliflozin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 187, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T05:41:44.827Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02429258", "title": "Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type II Diabetes" ], "interventions": [ { "name": "Farxiga", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 226, "start_date": "2015-05", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429258" }, { "nct_id": "NCT05762952", "title": "Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myocardial Ischemia" ], "interventions": [ { "name": "Dapagliflozin 10mg Tab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 40, "start_date": "2023-06-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05762952" }, { "nct_id": "NCT00546741", "title": "Drug Interaction With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Subjects" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Dapagliflozin + Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "Hamilton, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546741" }, { "nct_id": "NCT02419612", "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 444, "start_date": "2015-08-14", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419612" }, { "nct_id": "NCT04350593", "title": "Dapagliflozin in Respiratory Failure in Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Dapagliflozin 10 milligram (mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint Luke's Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1250, "start_date": "2020-04-22", "completion_date": "2021-06-11", "has_results": true, "last_update_posted_date": "2022-06-10", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 22, "location_summary": "Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04350593" }, { "nct_id": "NCT01002807", "title": "Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus (T2DM)" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "Glucophage", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 15, "start_date": "2009-11", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01002807" }, { "nct_id": "NCT03970044", "title": "Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Exenatide 2 MG", "type": "DRUG" }, { "name": "Dapagliflozin 10 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Consano Clinical Research, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 67, "start_date": "2019-07-02", "completion_date": "2021-06-01", "has_results": false, "last_update_posted_date": "2021-08-30", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "Shavano Park, Texas", "locations": [ { "city": "Shavano Park", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970044" }, { "nct_id": "NCT02796170", "title": "Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes", "Hypertension" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tulane University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2016-03", "completion_date": "2020-08", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796170" }, { "nct_id": "NCT02635386", "title": "EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polycystic Ovary Syndrome", "Obesity" ], "interventions": [ { "name": "Exenatide once weekly (EQW )", "type": "DRUG" }, { "name": "Dapagliflozin (DAPA)", "type": "DRUG" }, { "name": "EQW plus DAPA", "type": "DRUG" }, { "name": "Dapagliflozin plus Glucophage (MET ER)", "type": "DRUG" }, { "name": "Phentermine /Topiramate (PHEN/ TPM) ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woman's", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 119, "start_date": "2016-03-22", "completion_date": "2020-10-09", "has_results": true, "last_update_posted_date": "2021-01-29", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635386" }, { "nct_id": "NCT01606007", "title": "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo matching with Dapagliflozin", "type": "DRUG" }, { "name": "Placebo matching with Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1282, "start_date": "2012-07", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-02T05:41:44.827Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606007" } ] }